Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2012 Q1- Text added to 2012 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
Absorption, approved, April, biorepository, breakthrough, CE, Cetuximab, classified, commitment, coverage, diminished, diverse, efficacy, EGFR, enabling, Erlotinib, exhibit, extracted, extremely, fact, flat, frequent, human, incorporation, invasive, Italy, IVD, load, Logic, meaningful, modern, Panitumumab, platform, powerful, pushed, recruiting, repairing, resolved, resumed, revolutionize, saliva, short, significantly, strategic, successfully, Trademark, twenty, type, unmatched, valuable, vast, virtually
Valuein 2012 Q1 filing- Value in 2012 Q2 filing
Original filings
Filing view